Cargando…
Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors–Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment
Malignant pleural mesothelioma (MPM) is strongly associated with occupational or environmental asbestos exposure and arises from neoplastic transformation of mesothelial cells in the pleural cavity. The only standard initial treatment for unresectable MPM is combination chemotherapy with cisplatin (...
Autores principales: | Yoshikawa, Yoshie, Kuribayashi, Kozo, Minami, Toshiyuki, Ohmuraya, Masaki, Kijima, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767988/ https://www.ncbi.nlm.nih.gov/pubmed/33381446 http://dx.doi.org/10.3389/fonc.2020.554570 |
Ejemplares similares
-
Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2021) -
Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma – Comparison with contrast-enhanced CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2019) -
Deep learning with deep convolutional neural network using FDG-PET/CT for malignant pleural mesothelioma diagnosis
por: Kitajima, Kazuhiro, et al.
Publicado: (2021) -
Tumor‐associated macrophage‐derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma
por: Horio, Daisuke, et al.
Publicado: (2020) -
Should Lung-Sparing Surgery Be the Standard Procedure for Malignant Pleural Mesothelioma?
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)